Shanghai Jemincare Pharmaceuticals, Jiangxi Jemincare present new GTPase KRAS inhibitors April 13, 2021
Data from ongoing phase Ib/II study of onvansertib in second-line metastatic colorectal cancer April 12, 2021
Antengene initiates phase II study of ATG-008 in advanced solid tumors with genetic alterations April 12, 2021
Enrollment ongoing in phase I study of tomivosertib plus paclitaxel in advanced breast cancer April 12, 2021
Context Therapeutics and Integral Molecular collaborate to develop novel anti-CLDN6 antibodies April 12, 2021
RSS